JP2019521971A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521971A5 JP2019521971A5 JP2018563084A JP2018563084A JP2019521971A5 JP 2019521971 A5 JP2019521971 A5 JP 2019521971A5 JP 2018563084 A JP2018563084 A JP 2018563084A JP 2018563084 A JP2018563084 A JP 2018563084A JP 2019521971 A5 JP2019521971 A5 JP 2019521971A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- protide
- cpf
- leukemia
- derived
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 74
- 206010028980 Neoplasm Diseases 0.000 claims 46
- 201000011510 cancer Diseases 0.000 claims 45
- 238000000034 method Methods 0.000 claims 19
- 210000000130 stem cell Anatomy 0.000 claims 17
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 12
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 12
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 12
- 230000008685 targeting Effects 0.000 claims 11
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 9
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 9
- BIOWRMNRHMERIO-ZVAHOJSLSA-N benzyl (2s)-2-[[[(2r,3s,5r)-5-(5-fluoro-2,4-dioxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-naphthalen-1-yloxyphosphoryl]amino]propanoate Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)O)COP(=O)(N[C@@H](C)C(=O)OCC=2C=CC=CC=2)OC=2C3=CC=CC=C3C=CC=2)C=C(F)C(=O)NC1=O BIOWRMNRHMERIO-ZVAHOJSLSA-N 0.000 claims 9
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 9
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims 9
- 208000032839 leukemia Diseases 0.000 claims 9
- 230000002265 prevention Effects 0.000 claims 7
- NKGPJODWTZCHGF-KQYNXXCUSA-N 6-thioinosinic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(S)=C2N=C1 NKGPJODWTZCHGF-KQYNXXCUSA-N 0.000 claims 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 6
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 6
- 229960002436 cladribine Drugs 0.000 claims 6
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 claims 5
- 208000006994 Precancerous Conditions Diseases 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- MHDPPLULTMGBSI-UUOKFMHZSA-N (2r,3r,4s,5r)-2-(6-amino-8-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound ClC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MHDPPLULTMGBSI-UUOKFMHZSA-N 0.000 claims 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 3
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims 3
- 206010014733 Endometrial cancer Diseases 0.000 claims 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 3
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 3
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 201000004462 Leydig Cell Tumor Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010029260 Neuroblastoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 3
- 201000009036 biliary tract cancer Diseases 0.000 claims 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 3
- 201000010881 cervical cancer Diseases 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 229960000928 clofarabine Drugs 0.000 claims 3
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims 3
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims 3
- 229960000390 fludarabine Drugs 0.000 claims 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 3
- NHTKGYOMICWFQZ-BBOXMAMFSA-N fosgemcitabine palabenamide Chemical compound C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 NHTKGYOMICWFQZ-BBOXMAMFSA-N 0.000 claims 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 201000000849 skin cancer Diseases 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 208000019065 cervical carcinoma Diseases 0.000 claims 1
- 201000010255 female reproductive organ cancer Diseases 0.000 claims 1
- 229940029575 guanosine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022020897A JP2022051965A (ja) | 2016-06-01 | 2022-02-15 | がんの処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1609600.0A GB201609600D0 (en) | 2016-06-01 | 2016-06-01 | Cancer treatments |
| GB1609600.0 | 2016-06-01 | ||
| PCT/GB2017/051560 WO2017207993A1 (en) | 2016-06-01 | 2017-05-31 | Cancer treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020897A Division JP2022051965A (ja) | 2016-06-01 | 2022-02-15 | がんの処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521971A JP2019521971A (ja) | 2019-08-08 |
| JP2019521971A5 true JP2019521971A5 (enExample) | 2020-06-25 |
| JP7367910B2 JP7367910B2 (ja) | 2023-10-24 |
Family
ID=56410849
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563084A Active JP7367910B2 (ja) | 2016-06-01 | 2017-05-31 | がんの処置 |
| JP2022020897A Pending JP2022051965A (ja) | 2016-06-01 | 2022-02-15 | がんの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022020897A Pending JP2022051965A (ja) | 2016-06-01 | 2022-02-15 | がんの処置 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11400107B2 (enExample) |
| EP (1) | EP3463384A1 (enExample) |
| JP (2) | JP7367910B2 (enExample) |
| KR (2) | KR20190011770A (enExample) |
| CN (1) | CN109562119A (enExample) |
| AU (1) | AU2017273124B2 (enExample) |
| BR (1) | BR112018074981A2 (enExample) |
| CA (1) | CA3025442C (enExample) |
| CL (2) | CL2018003443A1 (enExample) |
| EA (1) | EA038030B1 (enExample) |
| GB (1) | GB201609600D0 (enExample) |
| IL (1) | IL263123B (enExample) |
| MA (1) | MA45129A (enExample) |
| MX (1) | MX2018014840A (enExample) |
| MY (1) | MY199129A (enExample) |
| PH (1) | PH12018502491A1 (enExample) |
| SG (1) | SG11201810196RA (enExample) |
| WO (1) | WO2017207993A1 (enExample) |
| ZA (1) | ZA201807811B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3447061T3 (da) | 2011-03-01 | 2022-01-03 | NuCana plc | Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling |
| CN111909231B (zh) | 2014-11-28 | 2025-10-17 | 努卡那有限公司 | 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物 |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
| AU2019360210B2 (en) * | 2018-10-17 | 2025-07-10 | Xibin Liao | 6-Mercaptopurine nucleoside analogues |
| JP2020164521A (ja) * | 2019-03-29 | 2020-10-08 | 国立大学法人 長崎大学 | 抗ウィルス薬 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| AU2021224588B2 (en) | 2020-02-18 | 2024-07-18 | Gilead Sciences, Inc. | Antiviral compounds |
| JP7688152B2 (ja) | 2021-04-16 | 2025-06-03 | ギリアード サイエンシーズ， インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
| JP7719954B2 (ja) | 2021-08-18 | 2025-08-06 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物並びにその製造方法及び使用方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| GB0505781D0 (en) * | 2005-03-21 | 2005-04-27 | Univ Cardiff | Chemical compounds |
| WO2007056596A2 (en) | 2005-11-09 | 2007-05-18 | Wayne State University | Phosphoramidate derivatives of fau |
| CN104586832B (zh) | 2007-09-10 | 2018-02-16 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| EP2274617A4 (en) | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
| WO2012040126A1 (en) | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| DK3447061T3 (da) | 2011-03-01 | 2022-01-03 | NuCana plc | Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling |
| AU2015265607A1 (en) | 2014-05-28 | 2016-11-17 | Idenix Pharmaceuticals Llc | Nucleoside derivatives for the treatment of cancer |
| KR102563040B1 (ko) * | 2014-06-25 | 2023-08-02 | 뉴카나 피엘씨 | 젬시타빈 전구 약물 |
| PT3119794T (pt) * | 2014-06-25 | 2018-01-15 | Nucana Biomed Ltd | Formulação que compreende um pró-fármaco de gemcitabina |
| CN111909231B (zh) * | 2014-11-28 | 2025-10-17 | 努卡那有限公司 | 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物 |
| KR20180021697A (ko) * | 2015-05-14 | 2018-03-05 | 뉴카나 피엘씨 | 암 치료 |
| GB201522764D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Formulations of phosphate derivatives |
| GB201609600D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| GB201715011D0 (en) | 2017-09-18 | 2017-11-01 | Nucana Biomed Ltd | Floxuridine synthesis |
-
2016
- 2016-06-01 GB GBGB1609600.0A patent/GB201609600D0/en not_active Ceased
-
2017
- 2017-05-31 CN CN201780048221.8A patent/CN109562119A/zh active Pending
- 2017-05-31 JP JP2018563084A patent/JP7367910B2/ja active Active
- 2017-05-31 KR KR1020187037533A patent/KR20190011770A/ko not_active Ceased
- 2017-05-31 WO PCT/GB2017/051560 patent/WO2017207993A1/en not_active Ceased
- 2017-05-31 KR KR1020227034733A patent/KR20220142538A/ko not_active Ceased
- 2017-05-31 MY MYPI2018002142A patent/MY199129A/en unknown
- 2017-05-31 MA MA045129A patent/MA45129A/fr unknown
- 2017-05-31 EP EP17728604.4A patent/EP3463384A1/en active Pending
- 2017-05-31 IL IL263123A patent/IL263123B/en unknown
- 2017-05-31 EA EA201892803A patent/EA038030B1/ru unknown
- 2017-05-31 US US16/305,162 patent/US11400107B2/en active Active
- 2017-05-31 SG SG11201810196RA patent/SG11201810196RA/en unknown
- 2017-05-31 AU AU2017273124A patent/AU2017273124B2/en active Active
- 2017-05-31 CA CA3025442A patent/CA3025442C/en active Active
- 2017-05-31 BR BR112018074981-8A patent/BR112018074981A2/pt not_active Application Discontinuation
- 2017-05-31 MX MX2018014840A patent/MX2018014840A/es unknown
-
2018
- 2018-11-20 ZA ZA2018/07811A patent/ZA201807811B/en unknown
- 2018-11-26 PH PH12018502491A patent/PH12018502491A1/en unknown
- 2018-11-30 CL CL2018003443A patent/CL2018003443A1/es unknown
-
2021
- 2021-10-12 CL CL2021002669A patent/CL2021002669A1/es unknown
-
2022
- 2022-02-15 JP JP2022020897A patent/JP2022051965A/ja active Pending
- 2022-08-01 US US17/878,747 patent/US20230218655A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180762T1 (hr) | Liječenje karcinoma | |
| Postmus et al. | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | |
| JP2018515618A5 (enExample) | ||
| JP2014177455A5 (enExample) | ||
| GEP20237479B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| JP2016518337A5 (enExample) | ||
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| JP2010209081A5 (enExample) | ||
| BR112016015848A2 (pt) | Composto, combinação de um composto, e, composição farmacêutica | |
| HRP20191461T1 (hr) | Novi 2' i/ili 5' derivati 3'-deoksi adenozina supstituirani aminokiselinskim esterom fosforamidata, kao antikancerogenog spoja | |
| EP3915583A4 (en) | COMBINED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS | |
| CY1116645T1 (el) | Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| SA518400552B1 (ar) | مركبات فوسفوراميدات | |
| WO2016080810A3 (ko) | 바이구아나이드 화합물 및 이의 용도 | |
| Froeling et al. | Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| WO2015054600A3 (en) | Glycan-interacting compounds and methods of use | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| JOP20190234B1 (ar) | مركب كبير الحلقات واستخداماته | |
| WO2015158890A3 (en) | Pancreatic cancer therapy and diagnosis | |
| EA201891473A1 (ru) | Комбинированная терапия | |
| WO2017053555A8 (en) | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs | |
| Godinho-Pereira et al. | A drug screening reveals minocycline hydrochloride as a therapeutic option to prevent breast cancer cells extravasation across the blood–brain barrier | |
| EP3689327C0 (fr) | Composition pharmaceutique dans le traitement de lésions pulmonaires |